1-(bromomethyl)-3-(fluoromethyl)benzene | 612057-33-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(bromomethyl)-3-(fluoromethyl)benzene
• 英文别名: 1-Bromomethyl-3-fluoromethyl-benzene
• CAS: 612057-33-7
• 化学式: C₈H₈BrF
• 分子量: 203.054
• InChiKey: JZHLREFAOWMDMS-UHFFFAOYSA-N

物化性质

• 沸点：
  234.0±20.0 °C(Predicted)
• 密度：
  1.443±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(bromomethyl)-3-(fluoromethyl)benzene 在 三乙酰氧基硼氢化钠 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl 2-((tert-butoxycarbonyl)amino)-4-((2-((3-fluorobenzyl)oxy)benzyl)(2-((3-(fluoromethyl)benzyl)oxy)benzyl)amino)butanoate
  参考文献：
  名称：

  [ 18 F] FABABA 的放射合成、体外和初步生物学评估，这是一种基于 PET 示踪剂的新型 ASCT-2 抑制剂。

  摘要：

  介绍 肿瘤的代谢改变使得通过正电子发射断层扫描显示后者成为可能，从而实现诊断并提供代谢信息。丙氨酸丝氨酸半胱氨酸转运蛋白 2 (ASCT-2) 是谷氨酰胺的主要转运蛋白，在多种肿瘤中上调。因此，针对这种转运蛋白的良好正电子发射示踪剂将具有重大价值。因此，本研究的目的是开发一种氟 18 标记的 V-9302 类似物，它是最有效的 ASCT-2 抑制剂之一。方法 通过相应苄基溴的亲核取代，用氟 18 标记前体。在 PC-3 和 F98 细胞系中用 [3 H] 谷氨酰胺对冷参考产品进行体外测定，以确定对人和大鼠丙氨酸丝氨酸半胱氨酸转运蛋白 2 的亲和力。为了评估示踪剂的潜力，在前列腺癌的小鼠异种移植模型中获取了动态 μPET 图像。结果 示踪剂可以以 3.66 ± 1.90 % 的整体非衰减校正产率合成。体外实验显示 PC-3 和 F98 细胞的抑制剂常数 Ki 分别为 90 μM 和 125 μM。PC-3

  DOI：

  10.1002/jlcr.3863
• 作为产物：
  描述：

  间二溴苄 在 四丁基氟化铵 作用下， 以 乙腈 为溶剂， 以45%的产率得到1-(bromomethyl)-3-(fluoromethyl)benzene
  参考文献：
  名称：

  Highly Efficient One-Pot Labeling of New Phosphonium Cations with Fluorine-18 as Potential PET Agents for Myocardial Perfusion Imaging

  摘要：

  Lipophilic cations such as phosphonium salts can accumulate in mitochondria of heart in response to the negative inner-transmembrane potentials. Two phosphonium salts [F-18]FMBTP and [F-18]mFMBTP were prepared and evaluated as potential myocardial perfusion imaging (MPI) agents in this study. The cations were radiolabeled via a simplified one-pot method starting from [F-18]fluoride and followed by physicochemical property tests, in vitro cellular uptake assay, ex vivo mouse biodistribution, and in vivo rat microPET imaging. The total radiosynthesis time was less than 60 min including HPLC purification. The [F-18] labeled compounds were obtained in high radiolabeling yield (similar to 50%) and good radiochemical purity (>99%). Both compounds were electropositive, and their log P values at pH 7.4 were 1.16 +/- 0.003 (n = 3) and 1.05 +/- 0.01 (n = 3), respectively. Both [F-18]FMBTP and [F-18]mFMBTP had high heart uptake (25.24 +/- 2.97% ID/g and 31.02 +/- 0.33% ID/g at 5 min postinjection (p.i.)) in mice with good retention (28.99 +/- 3.54% ID/g and 26.82 +/- 3.46% ID/g at 120 min p.i.). From the PET images in rats, the cations exhibited high myocardium uptake and fast clearance from liver and small intestine to give high-contrast images across all time points. These phosphonium cations were radiosynthesized via a highly efficient one-pot procedure for potential MPI offering high heart accumulation and rapid nontarget clearance.

  DOI：

  10.1021/mp500216g

文献信息

• Oxindole derivatives
  申请人：Luk Kim-Chun

  公开号：US20060293319A1

  公开（公告）日：2006-12-28

  The invention describes compounds of the general formula I or the pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and X are herein described, a process for their manufacture, medicaments containing them as well as the use of these compounds as pharmaceutically active agents. The compounds show activity as antiproliferative agents and may be especially useful for the treatment of cancer.

  这项发明描述了一般式I的化合物或其药用盐，其中R1、R2、R3和X在此处描述，以及它们的制备方法、含有它们的药物以及将这些化合物用作药用活性剂的用途。这些化合物显示出抗增殖剂的活性，可能特别适用于癌症的治疗。
• BICYCLOAMINE DERIVATIVES
  申请人：Ozaki Fumihiro

  公开号：US20090270369A1

  公开（公告）日：2009-10-29

  Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R 1 , R 2 and R 3 represent hydrogen, etc., X 1 represents C 1-6 alkylene, etc., X 2 represents C 1-6 alkylene, etc., A 1 represents a 5- to 6-membered heterocyclic group, etc., and A 2 represents C 6-14 aryl, etc.

  由式(I)表示的化合物及其药学上可接受的盐具有出色的钠通道抑制作用，并可用作治疗剂和各种神经痛、神经病、癫痫、失眠、早泄等的镇痛剂。其中Q代表乙烯等，R1、R2和R3代表氢等，X1代表C1-6烷基等，X2代表C1-6烷基等，A1代表5-至6-成员杂环基团等，A2代表C6-14芳基等。
• BICYCLOAMINE DERIVATIVE
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2241567A1

  公开（公告）日：2010-10-20

  Compounds represented by formula (I) and pharmaceutically acceptable salts thereof have excellent sodium channel inhibitory action and are useful as therapeutic agents and analgesics for various kinds of neuralgia, neuropathy, epilepsy, insomnia, premature ejaculation and the like. wherein Q represents ethylene, etc., R1, R2 and R3 represent hydrogen, etc., X1 represents C1-6 alkylene, etc., X2 represents C1-6 alkylene, etc., A1 represents a 5- to 6-membered heterocyclic group, etc., and A2 represents C6-14 aryl, etc.

  式 (I) 所代表的化合物及其药学上可接受的盐类具有出色的钠通道抑制作用，可用作各种神经痛、神经病、癫痫、失眠、早泄等疾病的治疗剂和镇痛剂。 其中 Q 代表乙烯等，R1、R2 和 R3 代表氢等，X1 代表 C1-6 亚烷基等，X2 代表 C1-6 亚烷基等，A1 代表 5 至 6 元杂环基团等，A2 代表 C6-14 芳基等。
• OXINDOLE DERIVATIVES
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1896412A2

  公开（公告）日：2008-03-12
• US7576082B2
  申请人：——

  公开号：US7576082B2

  公开（公告）日：2009-08-18